Bridgebio Pharma Stock Performance
| BBIO Stock | USD 28.54 0.77 2.77% |
On a scale of 0 to 100, BridgeBio Pharma holds a performance score of 5. The firm shows a Beta (market volatility) of 1.59, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BridgeBio Pharma will likely underperform. Please check BridgeBio Pharma's jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether BridgeBio Pharma's price patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in BridgeBio Pharma are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady forward indicators, BridgeBio Pharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 4.83 | Five Day Return 6.48 | Year To Date Return (31.35) | Ten Year Return 0.8 | All Time Return 0.8 |
1 | BridgeBio Pharma, Inc. Receives 47.92 Average PT from Analysts | 10/03/2024 |
2 | Disposition of 28148 shares by Neil Kumar of BridgeBio Pharma at 24.4 subject to Rule 16b-3 | 10/17/2024 |
3 | Disposition of 778 shares by Stephenson Brian C of BridgeBio Pharma subject to Rule 16b-3 | 11/15/2024 |
4 | Insider Sell Alert Brian Stephenson Sells Shares of BridgeBio Pharma Inc | 11/21/2024 |
5 | Disposition of 6704 shares by Stephenson Brian C of BridgeBio Pharma subject to Rule 16b-3 | 11/22/2024 |
6 | Disposition of 200 shares by Scott Randal W. of BridgeBio Pharma at 29.475 subject to Rule 16b-3 | 11/25/2024 |
7 | What is Leerink Partnrs Forecast for BBIO FY2024 Earnings | 11/27/2024 |
8 | BridgeBio Pharma Stock Surges on FDA Approval of Lead Treatment - TipRanks | 12/02/2024 |
9 | Acquisition by Thomas Trimarchi of 50000 shares of BridgeBio Pharma subject to Rule 16b-3 | 12/10/2024 |
10 | Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy | 12/13/2024 |
11 | BridgeBio Pharmas Buy Rating Reiterated at HC Wainwright | 12/19/2024 |
| Begin Period Cash Flow | 416.9 M |
BridgeBio |
BridgeBio Pharma Relative Risk vs. Return Landscape
If you would invest 2,451 in BridgeBio Pharma on September 25, 2024 and sell it today you would earn a total of 326.00 from holding BridgeBio Pharma or generate 13.3% return on investment over 90 days. BridgeBio Pharma is currently generating 0.2615% in daily expected returns and assumes 3.6436% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than BridgeBio, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BridgeBio Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BridgeBio Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BridgeBio Pharma, and traders can use it to determine the average amount a BridgeBio Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0718
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BBIO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.64 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.26 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average BridgeBio Pharma is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BridgeBio Pharma by adding it to a well-diversified portfolio.
BridgeBio Pharma Fundamentals Growth
BridgeBio Stock prices reflect investors' perceptions of the future prospects and financial health of BridgeBio Pharma, and BridgeBio Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BridgeBio Stock performance.
| Return On Equity | -17.9 | ||||
| Return On Asset | -0.49 | ||||
| Profit Margin | (2.02) % | ||||
| Operating Margin | (68.50) % | ||||
| Current Valuation | 6.48 B | ||||
| Shares Outstanding | 188.99 M | ||||
| Price To Earning | (13.72) X | ||||
| Price To Book | 123.68 X | ||||
| Price To Sales | 22.99 X | ||||
| Revenue | 9.3 M | ||||
| Gross Profit | 74.21 M | ||||
| EBITDA | (565.47 M) | ||||
| Net Income | (643.2 M) | ||||
| Cash And Equivalents | 715.71 M | ||||
| Cash Per Share | 4.83 X | ||||
| Total Debt | 1.74 B | ||||
| Debt To Equity | 4.61 % | ||||
| Current Ratio | 5.46 X | ||||
| Book Value Per Share | (6.51) X | ||||
| Cash Flow From Operations | (527.72 M) | ||||
| Earnings Per Share | (2.42) X | ||||
| Market Capitalization | 5.25 B | ||||
| Total Asset | 546.38 M | ||||
| Retained Earnings | (2.56 B) | ||||
| Working Capital | 333.75 M | ||||
| Current Asset | 513.67 M | ||||
| Current Liabilities | 51.37 M | ||||
About BridgeBio Pharma Performance
By examining BridgeBio Pharma's fundamental ratios, stakeholders can obtain critical insights into BridgeBio Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that BridgeBio Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 3.6 K | 3.8 K | |
| Return On Tangible Assets | (1.24) | (1.30) | |
| Return On Capital Employed | (1.51) | (1.58) | |
| Return On Assets | (1.18) | (1.24) | |
| Return On Equity | 0.47 | 0.50 |
Things to note about BridgeBio Pharma performance evaluation
Checking the ongoing alerts about BridgeBio Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BridgeBio Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BridgeBio Pharma had very high historical volatility over the last 90 days | |
| BridgeBio Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 9.3 M. Net Loss for the year was (643.2 M) with profit before overhead, payroll, taxes, and interest of 74.21 M. | |
| BridgeBio Pharma currently holds about 715.71 M in cash with (527.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.83. | |
| BridgeBio Pharma has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: BridgeBio Pharmas Buy Rating Reiterated at HC Wainwright |
- Analyzing BridgeBio Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BridgeBio Pharma's stock is overvalued or undervalued compared to its peers.
- Examining BridgeBio Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BridgeBio Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BridgeBio Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BridgeBio Pharma's stock. These opinions can provide insight into BridgeBio Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.